Gerresheimer company profile
Company profile
Gerresheimer has 13,301 employees and is headquartered in Düsseldorf, Germany.
Serving customers in Germany and internationally, Gerresheimer AG and its subsidiaries supply drug containment solutions across three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. Its range covers prefillable syringes, vials, glass cartridges and ampoules, plastic and glass packaging, and drug delivery devices such as inhalers and auto injectors, alongside diagnostic and medical products including point-of-care tests, lancing devices and infusion sets. Its customers include companies in pharma, biotech, medical technology, diagnostics, cosmetics, and food and beverage, as well as pharmacy chains, supermarkets and wholesalers.
In the fiscal year ended 30 November 2025, revenue reached EUR 2.3 billion, up 16.6% from the previous year, while the company posted a net loss of EUR 320.3 million. Gerresheimer had 13,301 employees and is headquartered in Düsseldorf, Germany, where it was founded in 1864.
Company facts
- Sector
- Materials
- Industry
- Medical Instruments & Supplies
- Country
- Germany
- Headquarters
- Peter-Müller-Straße 3, 40468, Düsseldorf
- Employees
- 13,301
- Chief executive
- Uwe Röehrhoff
- Founded
- 1864
- Fiscal year
- December - November
- Listing
- GXI · Xetra
- Currency
- EUR
- ISIN
- DE000A0LD6E6
- Website
- gerresheimer.com
Gerresheimer and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| GerresheimerGXI | Germany | $1.19B | 13,301 | 1.6% | — |
| Safilo GroupSFL | Italy | $972.72M | 3,368 | 7.2% | 19.1 |
| Bonesupport HoldingBONEX | Sweden | $2.03B | 174 | 25.5% | 78.1 |
| AddLifeALIF.B | Sweden | $2.11B | 2,428 | 8.9% | 33.5 |
| OttobockOBCK | Germany | $2.68B | 9,455 | 18.7% | 19.0 |
| Carl Zeiss MeditecAFX | Germany | $3.07B | 5,784 | 7.2% | 23.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
